OTS - Flu tests from R-Biopharm also detect new virus variants
2022. November 25. 11:17
Darmstadt, 25 November, 2022 (APA/OTS) - The flu season has begun
and different virus variants are also circulating in Germany. With
the flu tests from biotechnology company R-Biopharm, patients
quickly have certainty: Its RIDA®GENE Flu assays also reliably
detect the two novel variants. The company made the announcement
with regard to influenza A H1N1pdm09, which is circulating
primarily in the United Kingdom, and the H3N2 subtype, which was
rampant in Denmark in the spring and is currently dominating
influenza activity in Germany.
"Mutations in the target gene (MP gene) can affect the
diagnostic performance of influenza screening assays, producing
false-negative test results," explains Dr. Andreas Simons, Head of
Product Management at R-Biopharm. " Alignments of the detection
systems we used with the described sequences of the two novel virus
variants showed no mismatches. Their reliable detection is not
affected by the described mutations."
This means laboratories can continue to reliably confirm or
rule out influenza infections using R-Biopharm's RIDA®GENE (PG0505,
PG0545, PG6825) assays. The tests are multiplex real-time RT-PCR
for the direct qualitative detection of influenza viruses.
About R-Biopharm
R-Biopharm AG, located in Darmstadt, is one of Germany's
leading biotechnology companies. Founded in 1988, the company is
family-run in the second generation and considers itself as a
pioneer for health and quality of life. Its aspiration: to provide
the highest possible precision, safety, clarity and certainty in
prevention, therapy and healing. To this end, R-Biopharm develops
technologies, products and solutions for Clinical Diagnostics,
Nutrition Care and Food and Feed Analytics - and does so in
internationally recognized top quality. R-Biopharm is the world
market leader for test systems in the field of allergen analysis.
R-Biopharm unites research, development and sales under one
roof in order to respond to ever new challenges with agile
processes and to accompany the steadily growing world population
into a new health era. The company is represented in more than 120
countries - through 29 subsidiaries and 120 distributors. It
employs around 1,400 people worldwide (690 at its headquarters in
Darmstadt) and was repeatedly recognized with the "Sustainability
Award" for sustainable and profitable growth.
- Picture is available at AP Images (http://www.apimages.com) -
Press contact:
Simone Feiler
Head of Corporate Brand Communication
https://r-biopharm.com/de/
https://r-biopharm.com/de/kontakt/presse/
https://r-biopharm.com/de/news-presse/download-galerie/
R-Biopharm AG
An der neuen Bergstraße 17
64297 Darmstadt
Phone: 0 61 51 - 81 02-538
Mobile: 0 160 - 55 273 60
Fax: 0 61 51 - 81 02-40
Email: s.feiler@r-biopharm.de
-------------------------------------------------------------------
Az OTS internetes oldalán található hírek, közlemények, fotók a
forrásmegjelöléssel (OTS) szabadon és korlátozás nélkül
felhasználhatók. Továbbközlés esetén a közzétevő köteles az átvett
anyagot tartalmának torzítása nélkül, félreérthetőséget,
rosszindulatú következtetéseket kizáró, az eredeti
szövegkörnyezetnek megfelelő módon feldolgozni és megjelentetni.
Az OTS hírek nem képezik az MTI hírkiadás részét, az MTI által
szó szerint továbbított tartalomért minden esetben a beadó a
felelős.
© Copyright MTI nonprofit Zrt.
Az OTS szolgáltatással kapcsolatban további információt a
(06-1) 441-9050 telefonszámon vagy a ots@mti.hu elektronikus
levelező címen kaphat.